Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC

NCT ID: NCT03404557

Last Updated: 2019-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

88 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-18

Study Completion Date

2019-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The M2iSH laboratory showed with two previous clinical trials that Crohn's Disease (CD) macrophages present i) a defect to control Adherent-Invasive Escherichia coli (AIEC) infection related to polymorphisms associated with CD; ii) a CD - specific cytokine secretion profile after an AIEC infection and intestinal inflammation dependent; iii) a modification of the response of CD macrophages at a basal state and after the AIEC infection. These results consolidate the hypothesis of a defect specific to CD macrophages.

That's why, the primary purpose of this study is to realize a proteomic analysis of macrophages of CD patients infected or not with AIEC and to compare them to Ulcerative Colitis (UC) patients and healthy volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The macrophages characterization will be realized at a basal state and in response or not to AIEC.

Investigator aimed to 1) better understand the differences between macrophages of CD patients, UC patients and healthy volunteers but also the impact of AIEC infection on these macrophages to provide key informations to detect and characterize the defect of these macrophages; 2) highlight one or several protein in CD macrophages that could represent, in a long term, a potential therapeutic target of CD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crohn's Disease patients group

44 patients

Proteomic analysis

Intervention Type OTHER

Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli

Ulcerative Colitis patients group

22 patients

Proteomic analysis

Intervention Type OTHER

Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli

Healthy volunteers group

22 patients

Proteomic analysis

Intervention Type OTHER

Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Proteomic analysis

Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Crohn's Disease or ulcerative colitis or healthy volunteers
* Age \> 18 years
* Patients benefiting from the health insurance plan
* Patients who can read and attest to understanding the information note and informed consent

Exclusion Criteria

* Pregnant or breastfeeding woman
* Under guardianship or curatorship
* Refusing the genetic part of the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Laboratoire M2Ish

UNKNOWN

Sponsor Role collaborator

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anthony BUISSON

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A00667-46

Identifier Type: OTHER

Identifier Source: secondary_id

CHU-370

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.